Drug Trial Radar · NCT04961567
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
562
Actual
Start
Jul 16, 2021
Primary completion
Sep 27, 2026
Study completion Mar 16, 2027
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jul 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: \- How many participants have an improvement in their symptoms after 52 weeks of treatment? Researchers will answer this and other questions by measuring the symptoms of SLE over time using a variety of scoring tools. These include the SLE Responder Index (SRI), the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K), the British Isles Lupus Activity Group-2004 index (BILAG-2004), and the BILAG-BASED Combined Lupus Assessment (BICLA), among others. Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and SLE have on the quality of life of participants using a group of questionnaires. The study will be done as follows: * After screening, participants will be randomized to receive either a high or low dose of litifilimab, or placebo. A placebo looks like the study drug but contains no real medicine. * All participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks. The treatment period will last 52 weeks. Participants will continue to take their standard of care medications. * Neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo. * There will be a follow-up safety period that lasts up to 24 weeks. * In total, participants will have up to 22 study visits. The total study duration for participants will be up to 80 weeks.
Conditions
- Lupus Erythematosus, Systemic
Interventions
LitifilimabDrug
Administered as specified in the treatment arm.
PlaceboDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52Time frame: Week 52
Locations
177 sites in 17 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Arizona Arthritis & Rheumatology Associates, P.C.
Glendale, Arizona
Care Access Research - Huntington BeachCare Access Research - Huntington Beach
Huntington Beach, California
Valerius Medical Group
Los Alamitos, California
The Practice of Medicine
Los Angeles, California
R. Srinivasan, M.D., Inc. dba Monterey Park Medical Center
Monterey Park, California
Neurovations
Napa, California
Joo-Hyung Lee MD
Orange, California
Medvin Clinical Research
Whittier, California
RASF - Clinical Research Center
Boca Raton, Florida
University of Florida
Gainesville, Florida
Vida Clinical Research
Kissimmee, Florida
University of Miami Miller School of Medicine
Miami, Florida
HMD Research, LLC
Orlando, Florida
Clinical Research of West Florida, Inc.
Tampa, Florida
The Emory Clinic Emory University
Atlanta, Georgia
Jefrey Lieberman, M.D., P.C.
Decatur, Georgia
Southeastern Rheumatology Alliance dba Arthritis Center of North Georgia
Gainesville, Georgia
RNA America Health Sciences
Gainesville, Georgia
EBGS Clinical Trials
Snellville, Georgia
Rush University Medical Center
Chicago, Illinois
Boston University School of Medicine
Boston, Massachusetts
DM Clinical Research - Boston
Brookline, Massachusetts
University of Massachusetts
Worcester, Massachusetts
Saint Louis Rheumatology
St Louis, Missouri
Arthritis & Osteoporosis Associates, PA
Freehold, New Jersey
Arthritis and Osteoporosis Associates of New Mexico
Las Cruces, New Mexico
DJL Clinical Research, PLLC
Charlotte, North Carolina
Carolina Arthritis Associates
Wilmington, North Carolina
University of Cincinnati
Cincinnati, Ohio
STAT Research
Dayton, Ohio
Piedmont Arthritis Clinic, P.A.
Greenville, South Carolina
Low Country Rheumatology, PA
Summerville, South Carolina
West Tennessee Research Institute
Jackson, Tennessee
Arthritis & Rheumatology Institute
Allen, Texas
Office of John P. Lavery M.D., PA
Allen, Texas
Tekton Research
Austin, Texas
Precision Comprehensive Clinical Research Solutions
Colleyville, Texas
R and H Clinical Research
Katy, Texas
Prime Clinical Research
Mansfield, Texas
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.